Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) received functional i/Blue systems from its contract design and development firm, Optel, which will be used to conduct in vivo studies and virtual demonstrations for evaluation by leading urologists.
The systems were intended to be used for demonstrations at the American Urological Association (AUA) meeting, as well as for a first-in-human study.
Due to the COVID-19 pandemic, this year’s AUA meeting has been cancelled. In place of the planned in-person demonstrations and meetings, Imagin will host virtual meetings to exhibit the i/Blue system’s features and performance, and to continue building relationships with urologists and key opinion leaders.
“Receiving these i/Blue systems is an exciting milestone and a major step forward,” Jim Hutchens, president and CEO of Imagin, said in a statement.
“While in-person meetings and demonstrations of our i/Blue system would have been ideal, we are fortunate to have technologies to enable virtual meetings so we can continue to collect valuable feedback on the system,” he added.
In addition, as medical institutions have suspended initiation of all medical device clinical studies, Imagin Medical is pursuing alternative, preclinical i/Blue system study options. The company will continue to pursue first-in-human studies when clinical trials are allowed to resume, potentially later this year.
